175 related articles for article (PubMed ID: 12649109)
1. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.
Raymond E; Fabbro M; Boige V; Rixe O; Frenay M; Vassal G; Faivre S; Sicard E; Germa C; Rodier JM; Vernillet L; Armand JP
Ann Oncol; 2003 Apr; 14(4):603-14. PubMed ID: 12649109
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.
Santisteban M; Buckner JC; Reid JM; Wu W; Scheithauer BW; Ames MM; Felten SJ; Nikcevich DA; Wiesenfeld M; Jaeckle KA; Galanis E;
J Neurooncol; 2009 Apr; 92(2):165-75. PubMed ID: 19066728
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Masi G; Falcone A; Di Paolo A; Allegrini G; Danesi R; Barbara C; Cupini S; Del Tacca M
Clin Cancer Res; 2004 Mar; 10(5):1657-63. PubMed ID: 15014016
[TBL] [Abstract][Full Text] [Related]
9. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Morise M; Niho S; Umemura S; Matsumoto S; Yoh K; Goto K; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Sep; 44(9):846-51. PubMed ID: 25057092
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Loghin ME; Prados MD; Wen P; Junck L; Lieberman F; Fine H; Fink KL; Metha M; Kuhn J; Lamborn K; Chang SM; Cloughesy T; DeAngelis LM; Robins IH; Aldape KD; Yung WK
Clin Cancer Res; 2007 Dec; 13(23):7133-8. PubMed ID: 18056194
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
[TBL] [Abstract][Full Text] [Related]
12. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan therapy in adults with recurrent or progressive malignant glioma.
Friedman HS; Petros WP; Friedman AH; Schaaf LJ; Kerby T; Lawyer J; Parry M; Houghton PJ; Lovell S; Rasheed K; Cloughsey T; Stewart ES; Colvin OM; Provenzale JM; McLendon RE; Bigner DD; Cokgor I; Haglund M; Rich J; Ashley D; Malczyn J; Elfring GL; Miller LL
J Clin Oncol; 1999 May; 17(5):1516-25. PubMed ID: 10334539
[TBL] [Abstract][Full Text] [Related]
14. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
Takimoto CH; Morrison G; Harold N; Quinn M; Monahan BP; Band RA; Cottrell J; Guemei A; Llorens V; Hehman H; Ismail AS; Flemming D; Gosky DM; Hirota H; Berger SJ; Berger NA; Chen AP; Shapiro JD; Arbuck SG; Wright J; Hamilton JM; Allegra CJ; Grem JL
J Clin Oncol; 2000 Feb; 18(3):659-67. PubMed ID: 10653882
[TBL] [Abstract][Full Text] [Related]
17. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
Gajjar A; Chintagumpala MM; Bowers DC; Jones-Wallace D; Stewart CF; Crews KR
Cancer; 2003 May; 97(9 Suppl):2374-80. PubMed ID: 12712459
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
de Jonge MJ; Sparreboom A; Planting AS; van der Burg ME; de Boer-Dennert MM; ter Steeg J; Jacques C; Verweij J
J Clin Oncol; 2000 Jan; 18(1):187-94. PubMed ID: 10623709
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Herben VM; Schellens JH; Swart M; Gruia G; Vernillet L; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1897-905. PubMed ID: 10561231
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
